Magnetar Financial LLC Eagle Pharmaceuticals, Inc. Transaction History

Magnetar Financial LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$41.72 - $51.34 $379,026 - $466,423	-9,085 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$37.02 - $51.28 $336,326 - $465,878	9,085 New	9,085 $386,000
Q4 2019 Feb 13, 2020	SELL	$54.32 - $64.31 $824,197 - $975,775	-15,173 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $18,051 - $20,333	-339 Reduced 2.19%	15,173 $858,000
Q2 2019 Aug 14, 2019	BUY	$46.61 - $58.45 $26,101 - $32,732	560 Added 3.75%	15,512 $864,000
Q1 2019 May 15, 2019	BUY	$38.66 - $51.82 $578,044 - $774,812	14,952 New	14,952 $755,000
Q4 2018 Feb 14, 2019	SELL	$36.72 - $67.73 $149,376 - $275,525	-4,068 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$66.65 - $83.86 $50,720 - $63,817	761 Added 23.01%	4,068 $282,000
Q2 2018 Aug 14, 2018	SELL	$51.25 - $76.62 $63,293 - $94,625	-1,235 Reduced 27.19%	3,307 $250,000
Q1 2018 May 15, 2018	BUY	$52.16 - $66.86 $17,317 - $22,197	332 Added 7.89%	4,542 $239,000
Q4 2017 Feb 14, 2018	BUY	$49.6 - $60.87 $208,816 - $256,262	4,210	4,210 $225,000

8.59M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $10.8M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Magnetar Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Magnetar Financial LLC with notifications on news.